TCRX
TScan Therapeutics·NASDAQ
--
--(--)
--
--(--)
TCRX fundamentals
During Q4 2025, TScan Therapeutics (TCRX) reported revenue of 2.57M, a YoY change of 286.02%. Net income was -22.98M, a YoY change of 35.83%. Click to view the full income statement and explore the company's earnings performance.
Income Statement
Q1,2020 | Q2,2020 | Q3,2020 | Q4,2020 | Q1,2021 | Q2,2021 | Q3,2021 | Q4,2021 | Q1,2022 | Q2,2022 | Q3,2022 | Q4,2022 | Q1,2023 | Q2,2023 | Q3,2023 | Q4,2023 | Q1,2024 | Q2,2024 | Q3,2024 | Q4,2024 | Q1,2025 | Q2,2025 | Q3,2025 | Q4,2025 | TTM |
|---|
Start Date | Jan 1, 2020 | Apr 1, 2020 | Jul 1, 2020 | Oct 1, 2020 | Jan 1, 2021 | Apr 1, 2021 | Jul 1, 2021 | Oct 1, 2021 | Jan 1, 2022 | Apr 1, 2022 | Jul 1, 2022 | Oct 1, 2022 | Jan 1, 2023 | Apr 1, 2023 | Jul 1, 2023 | Oct 1, 2023 | Jan 1, 2024 | Apr 1, 2024 | Jul 1, 2024 | Oct 1, 2024 | Jan 1, 2025 | Apr 1, 2025 | Jul 1, 2025 | Oct 1, 2025 | -- |
End Date | Mar 31, 2020 | Jun 30, 2020 | Sep 30, 2020 | Dec 31, 2020 | Mar 31, 2021 | Jun 30, 2021 | Sep 30, 2021 | Dec 31, 2021 | Mar 31, 2022 | Jun 30, 2022 | Sep 30, 2022 | Dec 31, 2022 | Mar 31, 2023 | Jun 30, 2023 | Sep 30, 2023 | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | -- |
Fiscal Year-End | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | -- |
Revenue | -- -- | -- -- | 290.00K -- | 795.00K -- | 2.03M -- | 2.85M -- | 2.41M +731.72% | 2.85M +258.99% | 3.02M +49.04% | 4.06M +42.42% | 3.36M +39.43% | 3.10M +8.44% | 6.80M +125.19% | 3.15M -22.39% | 3.89M +15.58% | 7.21M +132.99% | 566.00K -91.68% | 536.00K -82.97% | 1.05M -73.01% | 665.00K -90.78% | 2.17M +283.57% | 3.08M +473.88% | 2.51M +139.37% | 2.57M +286.02% | 10.32M -- |
Sales and Services Revenue | -- -- | -- -- | 290.00K -- | 795.00K -- | 2.03M -- | 2.85M -- | 2.41M +731.72% | 2.85M +258.99% | 3.02M +49.04% | 4.06M +42.42% | 3.36M +39.43% | 3.10M +8.44% | 6.80M +125.19% | 3.15M -22.39% | 3.89M +15.58% | 7.21M +132.99% | 566.00K -91.68% | 536.00K -82.97% | 1.05M -73.01% | 665.00K -90.78% | 2.17M +283.57% | 3.08M +473.88% | 2.51M +139.37% | 2.57M +286.02% | 10.32M -- |
Cost of Revenue | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Gross Profit | -- -- | -- -- | 290.00K -- | -290.00K -- | 2.03M -- | 2.85M -- | 2.41M +731.72% | -7.29M -2412.76% | 3.02M +49.04% | 4.06M +42.42% | 3.36M +39.43% | -10.44M -43.27% | 6.80M +125.19% | 3.15M -22.39% | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Operating Expenses | 5.64M -- | 5.62M -- | 7.46M -- | 8.61M -- | 9.95M +76.45% | 13.53M +140.87% | 18.25M +144.66% | 17.06M +98.21% | 19.18M +92.90% | 19.30M +42.69% | 19.94M +9.24% | 21.74M +27.49% | 29.55M +54.01% | 27.76M +43.81% | 28.64M +43.60% | 28.57M +31.38% | 31.94M +8.10% | 34.65M +24.83% | 33.67M +17.59% | 37.38M +30.84% | 38.42M +20.29% | 41.73M +20.43% | 39.56M +17.50% | 26.43M -29.30% | 146.14M -- |
Selling, General and Administrative Expenses | 1.34M -- | 1.11M -- | 1.65M -- | 2.64M -- | 2.61M +94.77% | 2.73M +144.70% | 4.05M +145.63% | 4.45M +68.42% | 4.49M +72.45% | 4.81M +76.38% | 4.91M +21.29% | 6.14M +38.04% | 7.77M +72.83% | 6.53M +35.84% | 5.89M +20.04% | 6.16M +0.36% | 7.08M -8.82% | 7.77M +19.02% | 7.41M +25.70% | 8.02M +30.20% | 8.63M +21.90% | 9.10M +17.01% | 7.87M +6.28% | 6.39M -20.40% | 31.99M -- |
General and Administrative Expenses | -- -- | -- -- | -- -- | 6.74M -- | -- -- | -- -- | -- -- | 13.83M +105.13% | -- -- | -- -- | -- -- | 20.35M +47.18% | -- -- | -- -- | 5.89M -- | 6.16M -69.72% | 7.08M -- | 7.77M -- | 7.41M +25.70% | 8.02M +30.20% | 8.63M +21.90% | 9.10M +17.01% | 7.87M +6.28% | 6.39M -20.40% | 31.99M -- |
Research and Development Expenses | 4.30M -- | 4.50M -- | 5.81M -- | 5.96M -- | 7.34M +70.75% | 10.80M +139.92% | 14.21M +144.38% | 12.61M +111.40% | 14.69M +100.16% | 14.49M +34.19% | 15.03M +5.81% | 15.60M +23.76% | 21.78M +48.26% | 21.23M +46.45% | 22.74M +51.29% | 22.41M +43.59% | 24.86M +14.13% | 26.88M +26.62% | 26.26M +15.48% | 29.35M +31.01% | 29.79M +19.84% | 32.63M +21.42% | 31.69M +20.66% | 20.04M -31.73% | 114.15M -- |
Operating Income | -5.64M -- | -5.62M -- | -7.17M -- | -7.81M -- | -7.92M -40.49% | -10.68M -90.15% | -15.84M -120.92% | -14.20M -81.84% | -16.16M -104.13% | -15.25M -42.77% | -16.58M -4.65% | -18.65M -31.31% | -22.74M -40.71% | -24.61M -61.42% | -24.75M -49.28% | -21.36M -14.52% | -31.37M -37.95% | -34.11M -38.62% | -32.62M -31.82% | -36.71M -71.90% | -36.25M -15.55% | -38.65M -13.31% | -37.05M -13.58% | -23.86M +35.01% | -135.81M -- |
Non-Operating Income (Loss) | 99.00K -- | 3.00K -- | 1.00K -- | 3.00K -- | 6.00K -93.94% | 5.00K +66.67% | 3.00K +200.00% | 2.00K -33.33% | 7.00K +16.67% | 149.00K +2880.00% | 333.00K +11000.00% | -74.00K -3800.00% | 180.00K +2471.43% | 565.00K +279.19% | 1.75M +425.83% | 1.74M +2456.76% | 1.23M +583.89% | 2.45M +334.16% | 2.73M +56.20% | 903.00K -48.22% | 2.12M +72.46% | 1.70M -30.66% | 1.34M -50.93% | 881.00K -2.44% | 6.05M -- |
Other Non-Operating Income (Loss) | -- -- | -- -- | 1.00K -- | 3.00K -- | 6.00K -- | 5.00K -- | 3.00K +200.00% | 2.00K -33.33% | 7.00K +16.67% | 149.00K +2880.00% | 534.00K +17700.00% | 901.00K +44950.00% | 1.14M +16128.57% | 1.53M +929.53% | -- -- | 4.24M +370.59% | -- -- | -- -- | -- -- | 7.32M +72.69% | -- -- | -- -- | -- -- | 6.05M -17.41% | -- -- |
Net Interest Expense | -99.00K -- | -3.00K -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | 201.00K -- | 975.00K -- | 956.00K -- | 969.00K -- | -1.75M -971.14% | 2.50M +156.00% | -1.23M -228.77% | -2.45M -353.15% | -2.73M -56.20% | 6.42M +157.17% | -2.12M -72.46% | -1.70M +30.66% | -1.34M +50.93% | 5.17M -19.52% | -- -- |
Interest Expense | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | 201.00K -- | 975.00K -- | 956.00K -- | 969.00K -- | 982.00K +388.56% | -2.91M -398.15% | 959.00K +0.31% | 952.00K -1.75% | 958.00K -2.44% | -2.87M +1.31% | 679.00K -29.20% | 689.00K -27.63% | 699.00K -27.04% | -2.07M +27.95% | -- -- |
Interest Income | 99.00K -- | 3.00K -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 2.73M -- | -5.40M -- | 2.19M -- | 3.40M -- | 3.69M +35.13% | -9.29M -71.90% | 2.80M +27.95% | 2.39M -29.81% | 2.04M -44.73% | -7.23M +22.13% | -- -- |
Pretax Income From Continuing Operations | -5.54M -- | -5.61M -- | -7.17M -- | -7.81M -- | -7.91M -42.89% | -10.67M -90.17% | -15.84M -120.91% | -14.20M -81.89% | -16.16M -104.20% | -15.10M -41.44% | -16.25M -2.56% | -18.72M -31.85% | -22.56M -39.66% | -24.05M -59.27% | -23.00M -41.56% | -19.61M -4.75% | -30.14M -33.59% | -31.66M -31.67% | -29.89M -29.96% | -35.81M -82.58% | -34.13M -13.22% | -36.95M -16.71% | -35.71M -19.48% | -22.98M +35.83% | -129.77M -- |
Income Tax Expense | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Net Income | -5.54M -- | -5.61M -- | -7.17M -- | -7.81M -- | -7.91M -42.89% | -10.67M -90.17% | -15.84M -120.91% | -14.20M -81.89% | -16.16M -104.20% | -15.10M -41.44% | -16.25M -2.56% | -18.72M -31.85% | -22.56M -39.66% | -24.05M -59.27% | -23.00M -41.56% | -19.61M -4.75% | -30.14M -33.59% | -31.66M -31.67% | -29.89M -29.96% | -35.81M -82.58% | -34.13M -13.22% | -36.95M -16.71% | -35.71M -19.48% | -22.98M +35.83% | -129.77M -- |
Net Income Attributable to Owners of the Company | -5.54M -- | -5.61M -- | -7.17M -- | -7.81M -- | -7.91M -42.89% | -10.67M -90.17% | -15.84M -120.91% | -14.20M -81.89% | -16.16M -104.20% | -15.10M -41.44% | -16.25M -2.56% | -18.72M -31.85% | -22.56M -39.66% | -24.05M -59.27% | -23.00M -41.56% | -19.61M -4.75% | -30.14M -33.59% | -31.66M -31.67% | -29.89M -29.96% | -35.81M -82.58% | -34.13M -13.22% | -36.95M -16.71% | -35.71M -19.48% | -22.98M +35.83% | -129.77M -- |
Net Income Attributable to Common Stockholders | -5.54M -- | -5.61M -- | -7.17M -- | -7.81M -- | -7.91M -42.89% | -10.67M -90.17% | -15.84M -120.91% | -14.20M -81.89% | -16.16M -104.20% | -15.10M -41.44% | -16.25M -2.56% | -18.72M -31.85% | -22.56M -39.66% | -24.05M -59.27% | -23.00M -41.56% | -19.61M -4.75% | -30.14M -33.59% | -31.66M -31.67% | -29.89M -29.96% | -35.81M -82.58% | -34.13M -13.22% | -36.95M -16.71% | -35.71M -19.48% | -22.98M +35.83% | -129.77M -- |
Other Comprehensive Income | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | 51.00K -- | -55.00K -- | -- -- | 6.00K -- | -2.00K -103.92% | -- -- |
Total Comprehensive Income | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -89.22M -- | -30.14M -- | -31.66M -- | -29.89M -- | -35.76M +59.92% | -34.18M -13.40% | -36.95M -16.71% | -35.70M -19.46% | -22.98M +35.74% | -129.82M -- |
Total Comprehensive Income Attributable to Owners of the Company | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -89.22M -- | -30.14M -- | -31.66M -- | -29.89M -- | -35.76M +59.92% | -34.18M -13.40% | -36.95M -16.71% | -35.70M -19.46% | -22.98M +35.74% | -129.82M -- |
Basic EPS | -7.13 -- | -6.18 -- | -7.16 -- | -- -- | -6.49 +8.98% | -7.69 -24.43% | -0.8 +88.83% | -0.59 -- | -0.67 +89.68% | -0.63 +91.81% | -0.67 +16.25% | -0.77 -30.51% | -0.93 -38.81% | -0.51 +19.05% | -0.24 +64.18% | -0.41 +46.75% | -0.32 +65.59% | -0.28 +45.10% | -0.25 -4.17% | -0.63 -53.66% | -0.26 +18.75% | -0.28 -- | -0.28 -12.00% | -0.4 +36.51% | -1.22 -- |
Basic EPS from Continuing Operations | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -0.24 -- | -- -- | -0.32 -- | -0.28 -- | -0.25 -4.17% | -- -- | -0.26 +18.75% | -0.28 -- | -0.28 -12.00% | -- -- | -- -- |
Diluted EPS | -7.13 -- | -6.18 -- | -7.16 -- | -- -- | -6.49 +8.98% | -7.69 -24.43% | -0.8 +88.83% | -- -- | -0.67 +89.68% | -0.63 +91.81% | -0.67 +16.25% | -- -- | -0.93 -38.81% | -0.51 +19.05% | -0.24 +64.18% | -- -- | -0.32 +65.59% | -0.28 +45.10% | -0.25 -4.17% | -- -- | -0.26 +18.75% | -0.28 -- | -0.28 -12.00% | -- -- | -- -- |
Diluted EPS from Continuing Operations | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -0.24 -- | -- -- | -0.32 -- | -0.28 -- | -0.25 -4.17% | -- -- | -0.26 +18.75% | -0.28 -- | -0.28 -12.00% | -- -- | -- -- |
You can ask Aime
What is the market's earnings forecast for TScan Therapeutics next quarter?What were the key takeaways from TScan Therapeutics's earnings call?What is TScan Therapeutics's gross profit margin?What does TScan Therapeutics do and what are its main business segments?What is the revenue and EPS growth rate for TScan Therapeutics year over year?What factors drove the changes in TScan Therapeutics's revenue and profit?What were the key takeaways from TScan Therapeutics’s earnings call?Did TScan Therapeutics beat or miss consensus estimates last quarter?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
